FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com

Analysts at StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

FibroGen Trading Down 0.9 %

FGEN stock opened at $0.39 on Monday. The firm has a market cap of $38.94 million, a PE ratio of -0.16 and a beta of 0.70. FibroGen has a 1 year low of $0.30 and a 1 year high of $2.93. The company has a fifty day simple moving average of $0.39 and a 200 day simple moving average of $0.84.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. The business had revenue of $50.64 million for the quarter, compared to analyst estimates of $33.00 million. During the same period in the previous year, the company earned ($0.65) earnings per share. As a group, analysts forecast that FibroGen will post -0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On FibroGen

Hedge funds have recently bought and sold shares of the business. Alpine Global Management LLC acquired a new position in FibroGen during the first quarter worth $25,000. Delap Wealth Advisory LLC acquired a new position in FibroGen during the first quarter worth $27,000. Point72 DIFC Ltd grew its position in shares of FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 45,990 shares during the last quarter. Doheny Asset Management CA acquired a new stake in shares of FibroGen in the second quarter valued at about $48,000. Finally, Accel Wealth Management grew its position in shares of FibroGen by 117.5% in the second quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 51,645 shares during the last quarter. 72.71% of the stock is owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.